Variable Mean (SD)* n(%) P-value**
  Number of blood transfusions before TxR§ 0.80 (0.66) - -
Average time between TxR and VL (months) 21.3 (16.15) - -
Acute rejection episode 0.93 (0.74) - -
Blood transfusion before TxR
Yes   13(43.3) 0.465
No   17(56.7)
Blood type of recipient
Serotype O   14(46.7) 0.025
Serotype A   13(43.3)
Serotype B   3 (10.0)
Rh∞ factor of recipient
Positive   22(73.3) 0.011
Negative          8(26.7)
Incompatible mismatches, recipient–donor
≤ 3 mismatches   25(83.3) 0.001
> 3 mismatches   5 (16.7)
Use of prednisone
Yes   30 (100.0) -
No   0(0.0)
Use of azathioprine
Yes   6 (20.0) 0.001
No   22(80.0)
Use of cyclosporine
Yes   11(36.7) 0.200
No   19(63.3)
Use of tacrolimus
Yes   17(56.7) 0.565
No   13(43.3)
Use of MMF♯
Yes   27(90.0) 0.000
No   3(10.0)
Induction with monoclonal antibody
Yes   21(70.0) 0.043
No   9 (30.0)
Acute rejection post-transplantation
Yes   12(40.0) 0.362
No   18(60.0)
Patients with VL before TxR  
Yes   0. (0.0) -
No   30 (100.0)
CMV≠ infection post-transplantation
Yes   12(40.0) 0.362
No   18(60.0)
Bacterial infection post-transplantation
Yes   11(36.6) 0.002
No   19(73.4)
Recipient with positive serology for other viruses  
No   20(66.7) 0.068
Yes   10(27.0)
TxR§: renal transplantation; VL: visceral leishmaniasis; Rh∞: Rhesus factor; MMF♯, Mycophenolate mofetil; CMV≠: cytomegalovirus. **χ2 test. Mean (SD)*, Mean (SD), Mean (Standard Deviation); Categorial variables are reported as n (%)
Table 3: Clinical characteristics of 30 renal transplant recipients with posttransplantation Visceral Leishmaniasis.